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Oxygen is essential for the majority of multicellular organisms. As
such, variations in oxygen supply and demand within a given time
frame activate a variety of pathways, the ultimate aim of which is to re-
instate oxygen homeostasis. This is true at the organism level but also
true at the cellular level. Oxygen is required for efﬁcient ATP production
via oxidative phosphorylation in the mitochrondria, whilst ATP produc-
tion via glycolysis does not require oxygen, it is much less efﬁcient.
Hypoxia is an important stimulus for physiological processes such
as development and adaptation to high altitude living, but it is also an
36 A. Melvin, S. Rocha / Cellular Signalling 24 (2012) 35–43important factor in the pathology of many human diseases [1,2].
These include cancer, diabetes, ageing, and stroke/ischaemia [1,2].
Furthermore, it plays a role in the resistance to therapeutic
approaches such as radiotherapy [1,2].
Whilst the understanding of how whole organisms respond to
variations in oxygen availability has been greatly enhanced over the
last century, with physiology studies [3], the molecular understanding
of how oxygen is sensed at the cellular level is much more recent,
with the ﬁndings made thus far likely being the tip of the iceberg.
The research into oxygen sensing at the cellular level, was greatly
enhanced with the discovery of a family of transcription factors that
respond to hypoxia, called Hypoxia Inducible Factors (HIF) [1]. HIF
is a heterodimer of an oxygen labile subunit, HIF-α, and an oxygen-
insensitive HIF-1β, also known as aryl hydrocarbon nuclear translocator
(ARNT).
The tumour suppressor von Hippel Lindau (VHL), as part of the E3
ubiquitin ligase complex, targets HIF-α in the presence of oxygen to
be degraded by the proteasome. VHL recognises HIF-αmostly in nor-
moxia, through interaction with hydroxylated proline residues within
the oxygen-dependent degradation domain of HIF-α (Fig. 1). Bio-
chemical studies demonstrated that VHL has a 1000 fold increased
afﬁnity for hydroxylated HIF, compared to non-hydroxylated [4].
This speciﬁc modiﬁcation of prolines, is mediated by a class of dioxy-
genases, called Prolyl-Hydroxylases (PHDs). There are 3 PHDs that
have demonstrated effects on HIF, PHD1-3 and these enzymes require
molecular oxygen for their activity. Another dioxygenase with known
effects on HIF is the Factor Inhibiting HIF (FIH). FIH mediates the
hydroxylation of asparagine residues within the C-terminus transacti-
vation domains of HIF-α, preventing binding to co-activators such as
p300 or CBP [5], and thus limiting HIF transcriptional activity (Fig. 1).
HIF can activate many genes involved in many important cellular
processes such as cell cycle and cell growth, metabolism, oxygen
homeostasis, apoptosis and autophagy (Fig. 2). In fact, recent studies
using genomic chromatin immunoprecipitation (ChIP) techniques,
ChIP-on-ChIP and ChIP-Sequencing, have demonstrated hundreds of
genomic loci, where HIF binds [6,7], suggesting that many genes are
under the direct control of these transcription factors [6,7].
The importance of the HIF pathway has been extensively demon-
strated by genetic studies: HIF-1β null mice are embryonic lethal
with severe defects in many organs [8,9]. Furthermore, conditionalFig. 1. The HIF degradation pathway. In normoxia the hydroxylases (PHDs and FIH) use O2
C-Terminal Activation Domain (CTAD). Hydroxylation in the ODDD targets HIF-1α for ubiqu
proteasome. In moderate hypoxia the PHDs are inhibited causing HIF-1α accumulation and
sequent interaction of the HIF-1α-CTAD with co-activators such as p300/CBP.HIF-1β knockouts have been made in T-cells [10], β-cells [11] and
skin [12], and all of these tissues and cells have several defects. HIF-
1α null mice are also embryonic lethal, with defects in heart, brain,
vasculature and bone [13–15]. In addition, conditional deletion of HIF-
1α has been achieved in macrophages and neutrophils [16], neural cells
[17,18], keratinocytes [19], the colon [20] and the liver [21], to name a
few, and has been shown to be required for proper function of these tis-
sues. HIF-2α deleted mice present phenotypes that are strain speciﬁc
[22–24]. However, they all have severe defects in development.
All the PHDs have been deleted in mice, but only PHD2 is embry-
onic lethal with placental defects [25]. PHD2 also regulates the
vascular system in adult mice [26,27]. PHD1 null mice are apparently
normal, but demonstrate increased muscle fatigue [28], protection
against ischemic/reperfusion injury to the liver [29], and against coli-
tis [30]. PHD3 null mice are born but have defective sympathoadrenal
development and are systemically hypotensive [31]. More recently,
FIH was deleted in mice, and these were viable, with no apparent
developmental defects. Interestingly, FIH null mice have alterations in
their metabolism, presenting lower body weight, increased response
to insulin and importantly, protection against diet induced weight
gain [32]. These results suggest that FIH does not play a role in the con-
trol of HIF in developmental hypoxia but perhaps only in the case of
pathological hypoxia.
2. Chromatin structure
As mentioned before, HIF is an important transcription factor, and
as such it requires binding to DNA target sequences in the context of
chromatin. Chromatin is a dynamic and complex structure composed
of DNA and many proteins. The basic unit of chromatin is the nucleo-
some. The nucleosome consists of 147 bp of DNA wrapped around an
octomer of histones (2 copies of each of the core histones: H2A, H2B,
H3 and H4) [33,34]. Nucleosomes are linked with stretches of linker
DNA, which incorporate linker histones such as H1 [34]. Nucleosome
arrays are further compacted into higher order of chromatin, howev-
er detection and analysis methods for these higher order chromatin
structures are still not routinely available. In addition, there is no
detailed information on how chromatin structure changes in hypoxia.
There are two types of chromatin recognised according to its
compaction: heterochromatin and euchromatin. Heterochromatin, isto hydroxylate HIF-1α in the Oxygen Dependent Degradation Domain (ODDD) and the
itination by the VHL containing E3 ligase complex and HIF-1α is then degraded by the
its dimerisation with HIF-1β. Further decreases in oxygen cause FIH inhibition and sub-
Fig. 2. HIF induced transcriptional target and cellular pathways. HIF transcriptional targets are very diverse, involvingmany aspects of cellular regulation. It is the differential regulation of
these HIF target genes that allows for the diverse role of HIF, as well as, the integration of a wide variety of other cellular signals.
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with silent genes. On the other hand, euchromatin is characterised
by lower compaction and associated with actively transcribed genes
[35]. A recent biochemical analysis in the model organism Drosophila
has identiﬁed as many as 5 types of chromatin, two types of active
chromatin and 3 types of repressive chromatin [36]. Whether these
are present or not in mammalian cells, would require further
investigation.
Changes in chromatin are essential for the majority of cellular pro-
cesses that require access to DNA. These include transcription, DNA
replication and DNA repair. In order to access chromatin, organisms
have evolved a number of mechanisms whereby DNA-protein
contacts are relaxed or tightened depending on the requirement.
These mechanisms can be divided in to three broad categories: ATP-
dependent chromatin remodelling, post-translation modiﬁcation of
histones and incorporation of histone variants [37–39].
3. ATP-dependent chromatin remodellers in hypoxia
Cells have evolved a variety of enzymatic complexes that utilise
the energy of ATP to alter DNA-protein contacts, and hence chromatin
structure, according to their needs. These are called ATP-dependent
chromatin remodellers, and can change protein-DNA contacts to
move or remove nucleosomes. Based on homology and biochemical
properties, these enzymes can be divided into a variety of subtypes
but the most well characterised are: SWI/SNF (Switch/Sucrose Non-
Fermentable), ISWI (Imitation Switch), CHD/Mi-2 (chromodomain
helicase DNA-binding), and INO80 [40] (Fig. 3).Fig. 3. Human ATP dependent chromatin remodellers. The identity of chromatin remodelling
structure. All the ATPases shown here contain an ATPase domain (DExx and HELICc with an inser
an acetylated histone binding bromodomain. ISWI (Imitation Switch) contain SANT/SLIDE domain
bindmethylated lysine 4 in the histone H3 tail. INO80 are characterised by a larger insertion betw
and INO80. In humans there are multiple isoforms of each SNF2 family member that belong to an3.1. SWI/SNF
Perhaps themost studied family of chromatin remodellers, SWI/SNF,
is an evolutionary conserved multi-subunit complex (Fig. 4). It pos-
sesses one of two possible catalytic subunits, BRG1 or BRM, and a vari-
ety of accessory subunits that confer DNA binding and speciﬁcity [41].
It is mostly associated with activation of transcription but it is also nec-
essary to promote transcription repression in certain circumstances
[42]. Whilst BRG1 is essential for embryo development [43], BRM is
not [44]. In addition, some of its subunits have been found deleted or
mutated in a variety of cancers [45], further demonstrating their impor-
tance. Despite this, the function of these complexes in vivo, and in
particular, in response to a given stimuli is still not well understood.
This is also true in the context of hypoxia.
Very little information exists about chromatin structure and its
dynamics in hypoxia. However, two independent studies have
revealed important functions for SWI/SNF in the hypoxia response
[46,47]. Whilst BRM and BRG1 were found at the EPO promoter and
demonstrated to be required for HIF-mediated induction of this
gene [46]; BRG1 but not BRM was found at the HIF-1α gene itself
[47]. Importantly, SWI/SNF was shown to be required not only for
full HIF levels following hypoxia, but also required for hypoxia
induced cell cycle arrest [47]. The genetic knockout of the mouse ho-
mologue of BAF155, SRG3, has been published [48]. The mice show
peri-implantation lethality, with SRG3 being required for angiogene-
sis and visceral endoderm development. The genes deregulated were
identiﬁed as Angiopoietin1, Tie2 and EphrinB2 [48]. Angiopoetin and
Tie-2 are also deregulated in HIF-1β deleted mice [9]. However, thecomplexes is deﬁned by the ATPase subunit, which are in turn deﬁned by their unique
tion between them (grey)). Switch/Sucrose non fermentable (SWI/SNF) are characterised by
s. CHD/Mi-2 (chromodomain helicase DNA-binding) contains tandem chromodomains that
een the DExx and the HELICc regions. Helicase-SANT domains (HSA) are present in SWI/SNF
even more diverse set of ATPase complexes.
Fig. 4. Human ATPase Complexes and their composition. The ATPase subunits SWI/SNF, ISWI, CHD and INO80 form the catalytic centre to a wide variety of chromatin remodelling
complexes. The association of the non-catalytic subunits is thought to drive the speciﬁcity of the chromatin remodelling complexes. The catalytic subunit is indicated in bold.
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connection between BRG1 and vascularisation is further supported
with genetic studies where conditional deletion of BRG1was conducted
in the hematopoietic and endothelial cells. These mice showed impor-
tant defects in erythropoiesis and vascular development [49].
These studies demonstrated that chromatin and chromatin remo-
delling enzymes do play an active role in the cellular response to
hypoxia and should be further investigated.3.2. ISWI
ISWI is another important chromatin remodelling complex con-
served through evolution [35]. In humans, it is comprised of several
different complexes, sharing two possible catalytic subunits, hSNF2H
and hSNF2L (Fig. 3). In addition, accessory proteins (Fig. 4) deﬁne the
different complexes observed: NURF (nucleosome remodelling factor),
CHRAC (chromatin accessibility complex), ACF (ATP-dependent chro-
matin and remodelling factor), NoRC (nucleolar remodelling complex),
RSF (Remodelling and Spacing Factor) andWICH (WSTF–ISWI chroma-
tin remodelling complex). hSNF2H is essential for embryo development
with defects observed at the peri-implantation stage [50], however,
there is no information of the role of hSNF2L in development thus far.
ISWI is involved in a variety of important biological processes [51].
These include DNA replication and repair, regulation of transcription,
and regulation of chromosome structure [51]. In in vitro experiments
and in yeast, ISWI has been shown to promote even spacing of nucleo-
somes and as such has been thought asmostly a transcriptional repressor
[51]. In addition, one of ISWI's complexes RSF has been shown to promote
tumourigenesis and genomic instability [52,53].
ISWI function has not been investigated in the context of a given
stimulus thus far, and as such there is no information concerning
the involvement of ISWI in the cellular response to hypoxia. Further
work is therefore necessary to investigate in more detail how
chromatin remodellers such as ISWI are modulated by hypoxia.3.3. CHD/Mi-2
Mammalian CHD chromatin remodellers (Figs. 3, 4) all contain
chromodomains, which are involved in chromatin remodelling and
binding to methylated lysine residues [54]. Amongst the CHD family
members is the NuRD complex (nucleosome remodelling and histone
deacetylase) [37]. Despite being conserved in many organisms, CHD
function and in particular regulation are not well understood [37].
However, several of the CHD genes are required for embryo develop-
ment. These include CHD2 and CHD8. Furthermore, some of the CHD
genes are found mutated in human diseases such as the CHARGE syn-
drome (CHD7) [55]. In a recent study analysing gastric and colorectal
cancer, all CHD genes were found to be mutated [56]. Furthermore,
CHD5 promoter can be hypermethylated in Glioma, Breast and Colon
cancers [57]. These studies once again demonstrate the important role
of these complexes for normal cellular function.
Whilst there is no direct evidence that CHD complexes play a role
in the cellular response to hypoxia, different studies have demon-
strated that MTA1 (a member of the NURD complex (Fig. 4)) positively
correlates with HIF-1 activity and angiogenesis [58,59]. In addition,
MTA1 increases the levels of HIF-induced VEGF, an important HIF target
for promoting angiogenesis in tumours [59]. However, whether MTA1
regulation of HIF requires CHDmotor activity has not been investigated.
3.4. INO80
The INO80 family of chromatin remodellers is composed of three
different protein complexes, characterised by having an insertion in
their ATPase, creating a split-ATPase domain: INO80, SRCAP (SNF2-
related CBP activator protein) and TRRAP (transformation/transcrip-
tion domain-associated protein)/Tip60 (Fig. 4) [37]. These complexes
are involved in transcription regulation and DNA repair [60]. Of the
INO80 complexes known, only TRRAP has been reported to be essen-
tial for embryo development [61]. Interestingly, two components of
all INO80 complexes RuvBL1 (Pontin) and RuvBL2 (Reptin) have
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ate with Histone Acetyl Transferases (HATs) and Histone Deacetylases
(HDACs) and can regulate the activity of a number of important tran-
scription factors, notibly, c-myc, β-catenin and HIF-1α [62].
Whether the INO80 complexes play an active role in the cellular
response to hypoxia has not been formally investigated. However, an
interesting study by the Baek group has demonstrated that Reptin is
methylated by themethyl transferase Ga9 in hypoxia and that it associ-
ates with HIF-1 repressing a subset of HIF-dependent target genes in
hypoxia [63]. This suggests that at least Reptin plays a role in the
response to hypoxia. This group then demonstrated that aswith Reptin,
G9a couldmethylate Pontin in hypoxia but that this activated a different
set of HIF-dependent targets in hypoxia [64]. However, there was no
evidence that chromatin remodellingwas involved in this process, leav-
ing the question open as to whether the motor activity of these com-
plexes is required for any of the responses observed in hypoxia.
4. Post-translational histone modiﬁcations
One of the fastest ways of changing protein function is through
posttranslational modiﬁcations. Histone proteins are one of the most
conserved proteins known and are themselves targets of a multitude
of posttranslational modiﬁcations that act to alter contacts with DNA
or with other proteins. Histones can be ubiquitinated, sumoylated,
phosphorylated, acetylated, methylated, citrullinated and hydroxylated
[38]. Whilst some of these modiﬁcations have been associated with a
given function, many have not. Here we will focus on modiﬁcations
with known or possible roles in the hypoxia response.
4.1. Histone acetylation
Perhaps the best studied histone modiﬁcation, acetylation is
thought to add a charge to the histone, and hence loosen histone con-
tacts with DNA. In addition, acetylated histones create a binding site
for speciﬁc proteins such as chromatin remodellers that possess a
bromodomain [37,65]. Acetylation is a dynamic modiﬁcation, being
placed by HATs and removed by HDACs. For the majority of genes,
acetylation of histones correlates with active transcription and a more
open chromatin structure, such as the one found in euchromatin. On
the other hand, removal of acetylation associates with transcriptional
repression and heterochromatin.
Thus far, only one study has reported global changes in histone
acetylation in hypoxia [66]. However, this study used prolonged and
severe hypoxia conditions for their analysis. Nevertheless, speciﬁc
genes have been analysed for this modiﬁcation. For example, hypoxia
induces increases in acetylation in HIF target genes such as CA9 and
VEGF [67,68]. Furthermore, around 40% of HIF target genes are depen-
dent of HIF's association with the HAT p300 or CBP [69]. In addition to
HIF binding to p300/CBP, HIF has been shown to associate with other
HATs, for example PCAF and SRC-3 [70–72]. And these have shown to
be required for proper HIF transcriptional activation of its target genes.
Interestingly, HIF also binds toHDACs and these are required for prop-
er HIF activity [73]. Whilst some of these effects might be due to de-
acetylation of HIF or HIF associated proteins, histone de-acetylation
might also play a part. However, further studies are needed at HIF target
gene promoters to fully investigate these opposing effects of acetylation.
In addition, sirtuins, which are enzymes with histone deacetylase
activity [74], have been shown to be important for HIF activity. Sirt1
was shown to be required for HIF activity [75,76], whilst Sirt3 and
Sirt6 inhibit HIF [77–80]. In addition, Sirt1 was shown to be hypoxia
inducible [81].
4.2. Histone methylation
Unlike acetylation, methylation does not change the histone
charge. However it does alter the histone basic and hydrophobicproperties, changing its afﬁnity for proteins and creating binding
sites for certain speciﬁc protein domains such as plant homeodomain
or chromodomain [82]. Methylation is added to histones by methyl-
transferases, which can be divided into three types: SET domain
lysine methyltransferases; non-SET domain lysine transferases and
arginine methyltransferases [83]. The addition of these methyl groups
can result in both transcriptional activation and repression.
Only three of the known histone methyltransferases have been
studied in hypoxia, G9a, Suv39h, and PRMT2 [63,64,84–86]. Hypoxia
has been shown to increase G9a activity and levels [63,85]. Whilst
G9a was shown to be responsible for increased di-methylated H3K9
[85], increased G9a activity also induced methylation of non-histone
proteins [63], and this was responsible for speciﬁc HIF target gene re-
pression. Suv39h1 and Suv39h2 were recently shown to be important
methyltransferases that are induced by hypoxia, with critical roles in
embryo development [86]. In addition, PRMT2 was increased in mice
exposed to hypoxia [84]. Despite these interesting ﬁndings, there is no
information on the other histone methyl-transferases or any global
changes in their activity. Furthermore, their functional importance has
only been assessed in certain cases and further studies are needed to
ﬁrmly conclude the contribution of these enzymes towards the cellular
response to hypoxia.
Unlike acetylation, for many years, methylation was thought to be
an irreversible modiﬁcation. The ﬁrst histone demethylase that was
identiﬁed is the lysine-speciﬁc demethylase-1 (LSD1) [87]. Since
then this area of research has grown exponentially with the identiﬁ-
cation of the Jumonji C (JmjC) domain containing demethylases.
Importantly, in the context of this review, the JmjC containing
enzymes are α-ketoglutarate, Fe2+, dioxygenases, with a structure
very similar to that of FIH [88]. This indicates that this class of
demethylases are perfectly poised to respond to hypoxia.
Only a few studies have investigated changes in histonemethylation
after hypoxia. In addition, these studies have been done in different cel-
lular systems, different times of hypoxia exposure and different O2 con-
centrations. In the ﬁrst study, where histone methylation was analysed
at global levels, hypoxia was performed using nearly anoxic levels (0.2%
O2), and histone marks were analysed 48 h later. This study revealed
dramatic changes in both transcription and histone marks, with both
active and repressive marks being induced [66]. These results suggest
either a global increase in histone methyltransferase activity or a
decrease in histone demethylase function. An additional study, used
mouse macrophage cells to investigate changes in global and localised
histonemarks in inﬂammatory genes following 24 h of exposure to de-
creasing levels of oxygen [89]. This study found that changes in histone
methylation were visible only below 3% O2. It was found that H3K9 di-
and tri-methylation were increased and also H3K36 tri-methylation
was globally increased in macrophages following 24 hours exposure
to 1%O2 [89]. The authors suggest that thiswasdue to histone demethy-
lase inhibition at this oxygen concentration. A different study, investi-
gated H3K4 tri-methylation levels following hypoxia (1% O2) both
globally and locally [90]. Hypoxia induced increases in thismodiﬁcation
in all the cell lines analysed. The authors went on to show, that this in-
crease was due to inhibition of histone demethylase activity in hypoxia
[90]. These exciting new ﬁndings will pave the way for further studies
investigating global and localised histone methylation changes. The
combination of population and single cell analyses should provide addi-
tional information onhowhypoxiamodulates the chromatin landscape.
The identiﬁcation of JmjC demethylases suggests that chromatin will
react very rapidly to changes in oxygen but also to iron and metabolite
availability.
5. JmjC demethylases and hypoxia
There are over 100 proteins containing JmjC domains so far iden-
tiﬁed in different organisms [91]. In humans 30 such proteins have
been identiﬁed [92]. These enzymes can remove methyl groups
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[91,92]. Extensive studies in vitro and some studies in vivo, have
revealed some speciﬁcity for the JmjC demethylase (Table 1). Given
their enzymatic requirements for molecular oxygen, these proteins
are placed as perfect oxygen sensors, giving rise to the notion that
chromatin could act as an oxygen responsive structure. Moreover,
some of these enzymes are direct targets of the HIF transcription fac-
tor [93–97], further suggesting their functional involvement in the
response to hypoxia. In addition, themajority of the JmjC demethylases
are hypoxia inducible (Table 1).
The functional signiﬁcance of these enzymes towards the response
to hypoxia is only now being analysed, and given the great number of
enzymes, this task will be laborious. However, some evidence of their
signiﬁcance has already been demonstrated. For example, JMJD3Table 1
Name and function of human JmjC proteins and their connection with hypoxia. Gene name
U2OS cells (Melvin and Rocha, unpublished observations).
Human JmjC proteins Site speciﬁcity Hypoxia inducible Function
KDM2A/JHDM1A/FBXL-ll H3K36me1;H3K4me3 Y [120] Enhances D
Regulator o
KDM2B/JHDM1B/FBXL-l0 H3K36me1/2 Y [120] Potential tu
1.43 fold Regulates c
JHDM1D/KIAA1718 Y [120]
Y [125]
1.98 fold
PHF8 H3K9me1/2 Y [120] But it has p
Associated
PHF2 H3K9Me2 Maybe [120] Activated t
JMJD8/LOC339123
KDM3B/JMJDlB/JHDM2B H3K9me1/2 Y [120]
Y [125]
KDM3A/JMJD1A/JHDM2A H3K9me1/2 Y [125] Metabloic g
Y [96]
Y [129]
Y [89]
1.7 fold
JMJD1C Y [120]
−1.54 and +1.34 fold?
Hairless
JMJD4
JMJD6/PTDSR H3R2me2;H4R3me2 Y [120] Catalyses L
a Protein A
Y [125]
1.6 fold
HSPBAPl
HIFAN/FIHl HIF-1α No
KDM4C/JMJD2C/GASC1 H3K9/K36me2/3 Y [120] + In oesop
Y [125] RNAi reduc
1.8 fold
KDM4A/JMJD2A/JHDM3 H3K9/K36me2/3
KDM4B/JMJD2B H3K9me2/3 Y [120] Coordinate
hormonally
Y [96]
Y [89]
1.5 fold
KDM4D/JMJD2D H3K9me2/3 Y [89] Only up in
KDM5D/SMCY/JARID1D H3K4me2/3 Y [120]
KDM5C/SMCX/JARID1C H3K4me2/3 Y [120]
Y [125]
KDM5B/PLU-1/JARID1B H3K4me2/3 Y [120] + In breas
Y [125] RNAi reduc
1.45 fold
KDM5A/RBP-2/JARID1A H3K4me2/3 Y [120]
Y [125]
N [90] in BEAS-2B
KDM6A/UTX H3K27me2/3 Y [120]
UTY H3K27me2/3
KDM6B/JMJD3 H3K27me2/3 Y [120]
1.57 fold
JARID2 Y [120]
1.33 fold
JMJD7/PLA2G4-B −1.68 fold
JMJD5 Potential tu(KDM6B) knockout mice are lethal, indicating that this enzyme is
required for proper embryonic development [98]. Similarly, JMJD6,
Jarid2, JMJD2B (KDM4B), FBXL-10 (KDM2B), Hairless, JMJD1A
(KDM3A) all have reported defects in a variety of organs and cellular
processes [92]. PHF8 and Hairless are found mutated in human dis-
eases [99,100]. In addition, a systematic sequencing approach in
human renal cancers has identiﬁed UTX (KDM6A), Jarid1C (KDM5C)
as genes mutated in renal carcinoma [101,102].
JmjC speciﬁc action in hypoxia has been analysed in only a few
studies so far, with JMJD1A being the one mostly studied [94–97].
JMJD1A was found to be required for hypoxia induction of ADM and
GDF15 in renal and colon cancer cells [97]. In a separate study, Zhou
and colleagues demonstrated that hypoxia inhibits JARID1A
(KDM5A) to increase the levels of H3K4 tri-methylation [90].s are given in bold. Fold induction shown from microarray experiments conducted in
References
NA repair by nonhomologous end-joining. [121]
f rRNA transcription in response to starvation. [122]
mour suppressor [123]
ell proliferation and senescence through p15(Ink4b). [124]
referential binding of H3K4me3 [127]
with cleft lip/palate and mental retardation [126]
hrough PKA-mediated by phosphorylation [128]
ene expression and weight control [130,131] Identiﬁed by [132]
Array with KD — [133]
ysyl-Hydroxylation of U2AF65,
ssociated with RNA Splicing [134]
hageal sq. Carcinoma [135]
ed proliferation [136,137]
[138]
s H3K4/H3K9 methylation and promotes
responsive breast carcinogenesis. [139]
[139,140]
RAW264.7macrophages not peritoneal macrophages [89]
t and testis cancer [141,142]
es proliferation [143]
[90]
mour suppressor [123]
Table 2
Histone variants identiﬁed so far, their localisation and known genetic phenotype
(information adapted from [104]).
Variant Family Location Phenotype
H3.3 H3 Euchromatin, gene bodies,
promoters
H3T H3 Testes
CENP-A H3 Centromere Embryonic lethal
H2A.Z H2A Regulatory elements,
promoter, pericentric repeats
Embryonic lethal
H2A.X H2A XY Body, sites of double
strand DNA breaks
Male sterility, reduced
fecundity in females
macroH2A H2A Inactive X, promoters Severe brain malformations
(zebraﬁsh)
H2AL H2A Percentric repeats
H2A.Bbd H2A
TH2A Testes
TH2B H2B Testes
41A. Melvin, S. Rocha / Cellular Signalling 24 (2012) 35–43Furthermore, this was increased for hypoxia inducible targets such as
HOMX1 and DAF but not others [90]. However, no additional study
has combined siRNA, deletion or overexpression of other JmjC pro-
teins with hypoxia to determine their relevance in a given cell system.
Given their documented importance in development and human
disease, further studies are needed to determine the relative and
cell type contribution of these enzymes to chromatin organisation,
transcription rates and the cellular response to hypoxia.
6. Histone variants
As mentioned before, the basic unit of chromatin is the nucleo-
some, which is composed of two copies of each of the canonical his-
tones H3, H4, H2A and H2B. An additional mechanism to alter
chromatin structure and function is the replacement of canonical his-
tones with histone variants [39]. Amongst the canonical histones, only
H4 has no variant identiﬁed. Some histone variants only change by a
few residues, whilst other have considerable differences both at the
sequence and structural levels. Table 2 represents the known histone
variants, and their described roles and phenotypes. For an extensive
review please see [103,104].
Histone variants can mark areas of DNA damage such as H2Ax, or
important for cell division, for example CENPA [39]. In addition,
genetic studies have documented the importance of histone variants
for development [104]. In the context of hypoxia, only one variant
has been analysed and described, H2Ax [105,106]. In fact, a genetic
study has indicated that H2Ax is required for hypoxia induced neo-Fig. 5. Hypoxia and chromatin crosstalk. Many aspects of chromatin regulation are involve
p300/CBP and depends on histone de-acetylases HDACs for activation, as well as, repression
of HIF and HIF target genes, however, very little information exists for the roles of the other
tone methylation is an emerging area of hypoxia research as the JmjC de-methylases depend
are transcriptionally up-regulated by HIF. (−/+) indicates the known effects on transcriptivascularisation [105]. In addition, phosphorylated H2Ax has been
reported in many studies as a consequence of hypoxia induced ATR
activity [106]. Whether some other histone variants are deposited in
hypoxia or even play a role in the hypoxia response has not been
investigated.
7. DNA methylation
An additional mechanism to change chromatin and transcription
is by methylation of DNA itself. Generally, DNA methylation occurs
at CpG nucleotides, which are found in repetitive sequences in
genes but also with promoters of genes [107]. This modiﬁcation is
catalysed by DNA methyltransferases [108]. Like histone methylation,
DNA methylation is also dynamic, although the exact mechanism of
DNA demethylation is unknown, Basic Excision Repair (BER) enzymes
have been associated with the process of active DNA demethylation
[108].
Promoter hyper-methylation is associated with transcriptional si-
lencing, as the methylation prevents the binding of the majority of
transcription factors thus far investigated [107]. In addition, recent
studies have demonstrated that DNAmethylation inhibits the recruit-
ment of additional factors involved in transcriptional regulation such
as histone H3 K36 demethylase, KDM2A [109,110]. These studies
demonstrated an intrinsic connection between DNA and histone
methylation, to help orchestrate proper chromatin structure.
With regard with hypoxia, many studies have demonstrated that
promoter hypermethylation prevents HIF binding to its targets.
Such examples are: BNIP3, CA9, and PHD3 [111–115]. Globally hyp-
oxia has been shown to prevent DNA methylation by inhibition of
the expression of DNMT [116,117] and also by induction of MAT2A
[118]. However, exposure to chronic hypoxia in animal models has
been linked to increased DNA methylation proﬁles [119]. Again tem-
poral and cell type speciﬁc analyses will be required to properly
deﬁne the role of hypoxia in the control of DNAmethylation. In addition,
given the crosstalk between DNA and histonemethylation, it will be very
interesting to investigate how hypoxia regulates both pathways to obtain
the proper cellular response.
8. Summary
This review has summarised the crosstalk between hypoxia and
chromatin (Fig. 5). Chromatin could act as a primary oxygen sensor,
with changes in histone and protein methylation giving rise to further
structural changes in chromatin. As most of the hypoxia responses
rely on transcription, chromatin must accommodate rapid changesd in the modulation of HIF target genes in hypoxia. HIF recruits co-activators such as
. ATP dependent chromatin remodellers such as SWI/SNF are involved in the regulation
chromatin remodellers and to what extent HIF may interact/recruit them directly. His-
on oxygen for their activity. Furthermore, the majority of the 28 human JmjC proteins
on.
42 A. Melvin, S. Rocha / Cellular Signalling 24 (2012) 35–43in ATP supply and coordinate correct access of transcription factors to
the DNA sequences of its targets. Whilst chromatin structure has not
been studied in hypoxia thus far, global changes to histones have
been detected. Furthermore, the identiﬁcation of JmjC domain his-
tone demethylases as oxygen dependent enzymes, further supports
the idea that chromatin will sense oxygen changes rapidly (Fig. 5).
Exciting future work in these areas will most certainly reveal new
mechanisms by which hypoxia changes the cell's signalling pathways.
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